Relay Therapeutics, Inc. (NASDAQ: RLAY) reported Q4 EPS of ($0.56), $0.14 better than the analyst estimate of ($0.70). Revenue for the quarter came in at $250 thousand versus the consensus estimate of $233.33 thousand.

For earnings history and earnings-related data on Relay Therapeutics, Inc. (RLAY) click here.